Expression of the Epidermal Growth Factor Receptors and Ligands in Paired Samples of Normal Breast Tissue, Primary Breast Carcinomas and Lymph Node Metastases

Abstract

Purpose: In breast cancer, the EGF receptors host an increasing number of therapeutic targets and the interactive mechanisms of actions of the receptors and their ligands justify investigation of the EGF family as an entity. Experimental design: Paired tissue samples of normal breast tissue and primary breast carcinomas were examined in a prospective study of 163 patients. A third sample was obtained from the paired ipsilateral metastatic lymph node from 58 of these patients. The mRNA expression of four EGF receptors (HER1 -HER4) and 11 activating ligands was quantified with real-time RT-PCR. Results: Expression of HER2, HER3, and HER4 mRNA was upregulated in primary carcinomas compared to normal breast tissue while HER1 was downregulated. The mRNA expression of HER3 and HER4 differed between primary breast carcinomas and lymph node metastases whereas there was no difference in the expression of HER1 and HER2. The combination of low HER3 and low HER4 expression in the primary carcinoma was significantly more frequent in lymph node-negative patients as compared to lymph node positive patients. Distinct correlation patterns of the receptors and their corresponding activating ligands appeared in both normal breast tissue and in carcinomas, notably for the HER3 and HER4 receptors and their 3 specific ligands: HB-EGF, NRG2, and NRG4. Conclusion: HER2, HER3, and HER4 showed increased mRNA expression in carcinomas and were positively correlated to each other and to specific activating ligands. Furthermore, low HER3 and HER4 expression in the carcinomas correlated to the absence of lymph node metastases.

Regulatory dissection of the CBX5 and hnRNPA1 bi-directional promoter in human breast cancer cells reveals novel transcript variants differentially associated with HP1α down-regulation in metastatic cells

“…We next analysed the relationship between hnRNPA1 , HP1α-V3 and STET mRNA expression in breast cancer samples to see whether this corresponds to observations from breast cancer cell lines. cDNA was prepared from paired tissue samples from 193 patients with breast cancer [ 43 , 44 ]. 81 of the patients had metastases in the lymph nodes.…”

“…Breast tissue specimens were obtained from primary breast cancer surgical procedures as described [ 43 ]. The Regional Ethics Committee Northern Jutland, Denmark approved the study (N-20070047), and signed informed consent was obtained from each patient.…”

“…After synthesis the cDNA product was diluted with redistilled water to a total volume of 100 μl and stored at −20 °C. For breast cancer samples, cDNA was synthesized from RNA previously isolated from primary normal breast tissue, breast carcinomas and lymph node metastases [ 43 , 44 ]. cDNA was synthesized in a 20 μl reaction mix including 50 μmol/L Oligo(dT), reverse transcriptase (50 units/μL), RNase inhibitors (20 units/μL), 0.4 mmol/L of each dNTP, 1xPCR buffer, and 25 mmol/L MgCL2 (all from Applied Biosystems Inc., CA, USA).…”